Abstract: Objective To observe the efficacy and safety of butyiphthalide and nimodipine in the treatment of vascular dementia(VD). Methods Ninety cases with VD were randomly divided into group A(30 cases), group B(30 cases), and group C (30 cases). On the basis of conventional treatment, patients of group A were given 0.2 g butyiphthalide and 30 mg nimodipine for three times a day, group B were given 0.2 g butyiphthalide for three times a day, and group C were given 30 mg nimodipine for three times a day. All the patients were assessed with Montreal cognitive assessment scale (MoCA) and Activities of Daily Living (ADL) for comparison. The adverse events were recorded in the process of treatment. Results The MoCA and ADL Scores of three groups after treatment were better than scores before treatment, the differences were statistically signifucant (P<0.05). Group A could prominently improve the cognitive function of patients with VD, better than group C, the differences were statistically signifucant (P<0.05). Group A and B could prominently improve the cognitive function of patients with VD, better than group C, thedifferences were statistically signifucant (P<0.05). There was no statistically significant difference between A and B group (P>0.05). There were no significant differences in incidence rate of side effect among these groups. Conclusion Butyiphthalide and nimodipine can prominently improve the cognitive function of patients with vascular dementia and better than butyiphthalide or nimodipine alone. Combination therapy and given butyiphthalide alone can prominently improve the ability of daily living of patients with VD, which are better than nimodipine alone. Morever, their securities are good.

Key words: Vascular Dementia, Butyiphthalide, Nimodipine, efficacy, security